Skip to main content
. 2017 Jun 19;10:1179064417713197. doi: 10.1177/1179064417713197

Figure 2.

Figure 2

Targeting the NCKAP1-CYFIP1 interface suppresses metastasis in vivo. (A) Comparison of invasion potential of MDA-MB-231 cells using transwell assays comparing the original WANT3 peptide with 3 variants (v1-3) shows that the WANT3-v1 peptide is more efficient that the parent WANT3 peptide. *P < .05, **P < .01. (B) Relative intensities in the bioluminescence analysis of mice treated with the WANT3-v1 peptide show reduced spread of tumor cells over 28 days compared with mice treated with the scrambled (SCR) peptide. After completion of the treatment regimen, analysis of the lungs and liver shows reduced numbers of surface nodules (C, left) which was confirmed by histopathological analysis showing extensive infiltration in lung and liver in mice treated with the SCR control compared with the WANT3-v1 peptide (C, right). *P < .05, **P < .01.